These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 25511580)

  • 1. Effectiveness and safety of different duration of thromboprophylaxis in 16,865 hip replacement patients--a real-word, prospective observational study.
    Pedersen AB; Sorensen HT; Mehnert F; Johnsen SP; Overgaard S
    Thromb Res; 2015 Feb; 135(2):322-8. PubMed ID: 25511580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal duration of anticoagulant thromboprophylaxis in total hip arthroplasty: new evidence in 55,540 patients with osteoarthritis from the Nordic Arthroplasty Register Association (NARA) group.
    Pedersen AB; Andersen IT; Overgaard S; Fenstad AM; Lie SA; Gjertsen JE; Furnes O
    Acta Orthop; 2019 Aug; 90(4):298-305. PubMed ID: 31060431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Venous thromboembolism prophylaxis after total knee or hip replacement: treatment pattern and outcomes.
    Penning-van Beest FJ; Overbeek JA; Meijer WM; Woodruff K; Jackson J; van der Vis H; van der Linden P; Herings RM
    Pharmacoepidemiol Drug Saf; 2011 Sep; 20(9):972-8. PubMed ID: 21748826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of thromboprophylaxis with low-molecular-weight heparin or rivaroxaban in hip and knee replacement surgery: findings from the ORTHO-TEP registry.
    Beyer-Westendorf J; Lützner J; Donath L; Tittl L; Knoth H; Radke OC; Kuhlisch E; Stange T; Hartmann A; Günther KP; Weiss N; Werth S
    Thromb Haemost; 2013 Jan; 109(1):154-63. PubMed ID: 23197272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of thromboprophylaxis guidelines on clinical outcomes following total hip and total knee replacement.
    Selby R; Borah BJ; McDonald HP; Henk HJ; Crowther M; Wells PS
    Thromb Res; 2012 Aug; 130(2):166-72. PubMed ID: 22365491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risks and cost burden of venous thromboembolism and bleeding for patients undergoing total hip or knee replacement in a managed-care population.
    Vekeman F; LaMori JC; Laliberté F; Nutescu E; Duh MS; Bookhart BK; Schein J; Dea K; Olson WH; Lefebvre P
    J Med Econ; 2011; 14(3):324-34. PubMed ID: 21506632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased one-year risk of symptomatic venous thromboembolism following total hip replacement: a nationwide cohort study.
    Pedersen AB; Johnsen SP; Sørensen HT
    J Bone Joint Surg Br; 2012 Dec; 94(12):1598-603. PubMed ID: 23188898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended thromboprophylaxis with low-molecular-weight heparins after hospital discharge in high-risk surgical and medical patients: a review.
    Huo MH; Muntz J
    Clin Ther; 2009 Jun; 31(6):1129-41. PubMed ID: 19695383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The risk of venous thromboembolism, myocardial infarction, stroke, major bleeding and death in patients undergoing total hip and knee replacement: a 15-year retrospective cohort study of routine clinical practice.
    Pedersen AB; Mehnert F; Sorensen HT; Emmeluth C; Overgaard S; Johnsen SP
    Bone Joint J; 2014 Apr; 96-B(4):479-85. PubMed ID: 24692614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Venous thromboembolism prevention with fondaparinux 1.5 mg in renally impaired patients undergoing major orthopaedic surgery. A real-world, prospective, multicentre, cohort study.
    Mismetti P; Samama CM; Rosencher N; Vielpeau C; Nguyen P; Deygas B; Presles E; Laporte S;
    Thromb Haemost; 2012 Jun; 107(6):1151-60. PubMed ID: 22476471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial.
    Anderson DR; Dunbar MJ; Bohm ER; Belzile E; Kahn SR; Zukor D; Fisher W; Gofton W; Gross P; Pelet S; Crowther M; MacDonald S; Kim P; Pleasance S; Davis N; Andreou P; Wells P; Kovacs M; Rodger MA; Ramsay T; Carrier M; Vendittoli PA
    Ann Intern Med; 2013 Jun; 158(11):800-6. PubMed ID: 23732713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustment.
    Turpie AG; Haas S; Kreutz R; Mantovani LG; Pattanayak CW; Holberg G; Jamal W; Schmidt A; van Eickels M; Lassen MR
    Thromb Haemost; 2014 Jan; 111(1):94-102. PubMed ID: 24154549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness of direct oral anticoagulants versus low-molecular weight heparins for the prevention of venous thromboembolism after total hip or knee replacement: A nationwide database cohort study.
    Blin P; Samama CM; Sautet A; Benichou J; Lignot-Maleyran S; Lamarque S; Lorrain S; Lassalle R; Droz-Perroteau C; Mismetti P; Moore N
    Pharmacol Res; 2019 Mar; 141():201-207. PubMed ID: 30583081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thromboprophylaxis patterns, risk factors, and outcomes of care in the medically ill patient population.
    Mahan CE; Fisher MD; Mills RM; Fields LE; Stephenson JJ; Fu AC; Spyropoulos AC
    Thromb Res; 2013 Nov; 132(5):520-6. PubMed ID: 24080150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
    Kakkar VV; Howes J; Sharma V; Kadziola Z
    Thromb Haemost; 2000 Apr; 83(4):523-9. PubMed ID: 10780310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.
    Colwell C; Mouret P
    Semin Vasc Med; 2005 Aug; 5(3):266-75. PubMed ID: 16123914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective observational study on the effectiveness and safety of bemiparin, first dose administered 6 h after knee or hip replacement surgery.
    Abad JI; Gómez-Outes A; Martínez-González J; Rocha E;
    Arch Orthop Trauma Surg; 2007 Oct; 127(8):665-70. PubMed ID: 17089172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial.
    Eriksson BI; Dahl OE; Huo MH; Kurth AA; Hantel S; Hermansson K; Schnee JM; Friedman RJ;
    Thromb Haemost; 2011 Apr; 105(4):721-9. PubMed ID: 21225098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population-based epidemiology of postoperative venous thromboembolism in Taiwanese patients receiving hip or knee arthroplasty without pharmacological thromboprophylaxis.
    Wu PK; Chen CF; Chung LH; Liu CL; Chen WM
    Thromb Res; 2014 May; 133(5):719-24. PubMed ID: 24593913
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.